Long-term Safety and Tolerability of AFFITOPE AD02

NCT ID: NCT00711321

Last Updated: 2010-05-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the long-term tolerability and -safety of AFFITOPE AD02 applied during AFFiRiS 002

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

AFFITOPE AD02 with adjuvant

No interventions assigned to this group

1

AFFITOPE AD02 without adjuvant

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent signed and dated by patient and caregiver
* Patients having participated in AFF002 and having received at least 1 vaccination with AFFITOPE AD02
* Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits

Exclusion Criteria

* Patients having received no vaccination with AFFITOPE AD02
* History of questionable compliance to visit schedule, patients not expected to finish the clinical trial
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Affiris AG

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Margot Schmitz, MD Univ. D.

Role: PRINCIPAL_INVESTIGATOR

Ordination Schmitz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ordination Schmitz

Vienna, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EudraCT 2008-002764-33

Identifier Type: -

Identifier Source: secondary_id

Affiris 004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AD01 Follow up Extension Visit
NCT01225809 COMPLETED
Safety and Tolerability of AFFITOPE AD03
NCT01309763 COMPLETED PHASE1